Drug profile · INN
monomethyl fumarate
BAFIERTAM
monomethyl fumarate (BAFIERTAM) is a kelch-like ech-associated protein 1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — monomethyl fumarate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
monomethyl fumarate (BAFIERTAM) is a kelch-like ech-associated protein 1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Kelch-like ECH-associated protein 1 inhibitor
Primary target: Kelch-like ECH-associated protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is monomethyl fumarate?
monomethyl fumarate (BAFIERTAM) is a kelch-like ech-associated protein 1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for monomethyl fumarate?
BAFIERTAM is a marketed brand name for monomethyl fumarate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of monomethyl fumarate?
monomethyl fumarate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.